histogen


Also found in: Medical, Encyclopedia.

histogen

(ˈhɪstəˌdʒɛn)
n
(Botany) (formerly) any of three layers in an apical meristem that were thought to give rise to the different parts of the plant: the apical meristem is now regarded as comprising two layers. See corpus, tunica

his•to•gen

(ˈhɪs tə dʒən, -ˌdʒɛn)

n.
a region in a plant in which tissues differentiate.
[1920–25]
Mentioned in ?
References in periodicals archive ?
Histogen cell technology harnesses the power of growth factors and stem-cell signaling molecules for skin rejuvenation that complements Allergan's flagship growth factor technology - TNS, according to the company.
The judging panel was led by former Broadcom chairman John Major and Histogen founder and CEO Gail Naughton, and included representatives from UCSD's Rady School of Management, CSU San Marcos' School of Business and the La Jolla Institute, as well as several entrepreneurs who have successfully navigated the M&A process.
JAPAN: Histogen Aesthetics has entered into a licensing and distribution agreement with JPGH Co.
Naughton serves as the chief executive officer and the chair of the board of Histogen as well as a member of the board of directors for CR Bard.
With the trend toward avoiding the knife and treating skin on a cellular level, Histogen Aesthetics, a subsidiary of regenerative medicine company Histogen, Inc.
US Stratus Media Group Inc (OTCBB:SMDI) said it had inked a letter of intent (LoI) to buy regenerative medicine company Histogen Inc for an undisclosed sum.
Ziering serves on advisory boards for various companies including Merck, Lexington International and Viviscal, on the scientific advisory board of Histogen (a Regenerative Medicine company) and is on the Surgical Faculty for the Procedural Dermatology Fellowship at the University of California at Irvine, Dermatology Faculty, Western University/Pacific Hospital, Long Beach, California and Michigan State University, Dermatology Faculty.
Led by former Broadcom chairman John Major and Histogen founder and CEO Gail Naughton, judges included representatives of UCSD's Rady School of Management, CSU San Marcos' School of Business and the La Jolla Institute, as well as several entrepreneurs who have successfully navigated the M&A process.
Histogen will receive a transfer price on the CCM, as well as royalties on future sales of ReGenica and product line extensions.